Editas Medicine Inc
NASDAQ:EDIT
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
Editas Medicine Inc
NASDAQ:EDIT
|
463.6m USD | -1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 14.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 29.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 22.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 28 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 84.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 10.2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | -10.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -59.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 28.7 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 218.9 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.